The drug company Liochevax A/S (“Liochevax”) announced today the approval of lofexor Rx, a liquid biologic therapy and routine case management agent for breast cancer patients with trans- and metastatic localized stretch cancer.
The company will expand its manufacturing network as it assess the impact of the current cardiovascular adverse effects on its products, and evaluate other potential cardiovascular risks, including the impact of avoidable falls, injury, and unemployment, Liochevax said.
Liochevax previously received FDA approval for other thrombotic treatment agents, including portal venous thromboembolism unit for acute myeloid thrombocytopenia and cluster leukemia, as well as for chemoradiotherapy-targeted release agent for acute lymphoblastic leukemia and lymphocytic leukemia, to-date.
Liochevax previously received the Allergan erythromycin Croft-regimens/Cleniosus and Allergan abirateron/Clinogen approved safety profiles for acute myeloid thrombocytopenia and cluster cancer, and received the European Medicines Agency (EMA) safety profile for Cleniosus.
Liochevax is developing its own triate enzyme product in partnership with Infosys , which hopes to provide complementary cardiovascular benefits from lofexor.
Lofexor Rx will be available as either a separately-included or boxed set of four inhibitors for 41 years. A one-time dose-escalation strategy has been implemented with the proposed 5-year product life.
The company is also developing Andrapan, a combination lofexor inhibitor/anti-HIV combination therapy product, with potential for one-time-treatment, extended treatment, and two-year dosing, and intends to begin clinical assessments in early 2022. It expects to have accomplished proof-of-principle results in early 2025.
This product will be available in 5mL and 60mL vials. Pfizer, Moderna, Mylan NV, and Valneva Pharmaceuticals Plc, Inc. are developing Andrapan and also intend to start clinical assessments in Early 2020. Altogether, Liochevax products employ a broad array of cardiovascular and antimicrobial properties, according to its statement.